- Home
- MMD vs PBYI Comparison
MMD vs PBYI Comparison
Compare MMD & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMD | PBYI |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.7M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MMD | PBYI |
|---|---|---|
| Price | $14.93 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 74.7K | ★ 642.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.12 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.30 | $2.58 |
| 52 Week High | $17.67 | $6.12 |
Technical Indicators
Market Signals| Indicator | MMD | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 55.90 |
| Support Level | $14.82 | $4.84 |
| Resistance Level | $14.98 | $5.11 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 46.88 | 91.59 |
Price Performance
Historical ComparisonAbout MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund
NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.